
Cardinal Health
CAH · NYSE · Health Care
Quotes delayed up to 15 min. Updated 16 Nov, 16:00 New York time
- Market cap
- $65,0 bn
- Div. yield
- 1,9%
- Year to date
- +36,8%
Ratio score
Not enough data for a score
The score is calculated when at least 6 of 10 metrics are known.
Key metrics
1 ✓ · 0 — · 2 ✕ · 7 n/a · hover over a row or tap it to see the trend
All metrics
| Metric | Value | 5-year median | Industry median |
|---|---|---|---|
| P/E TTM | 35,7 | 27,7 | 25,1 |
| Forward P/E | 19,2 | — | 16,2 |
| PEG | 3,1 | — | 2,2 |
| P/S | 0,3 | 0,1 | 2,2 |
| EV/EBITDA | 23,2 | 19,8 | 17,3 |
| P/FCF | 13,3 | — | 19,5 |
| P/B | 65,1 | 5,9 | 3,4 |
Industry median — across 33 profitable companies in “Health Care” in Ratio. Revenue and EPS forecasts for future years and the number of employees are in the paid data plan.
Price chart
Compare with
Choose a stock
Closing prices adjusted for splits and dividends. The S&P 500 index and the intraday chart come later.
Analysts
Ratings, 22 analysts
- Buy
- 19
- Hold
- 3
- Sell
- 0
Beat the EPS forecast in 4 of the last 4 quarters
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| Q1 2027 | 2,97 | 3,26 | Up +9,8% |
| Q4 2026 | 2,44 | 2,60 | Up +6,4% |
| Q3 2026 | 2,82 | 3,17 | Up +12,6% |
| Q2 2026 | 2,40 | 2,63 | Up +9,4% |
Price targets and yearly revenue and EPS forecasts are in the paid data plan. These are analysts' opinions, not our verdict.
Financials in charts
| Metric | Q3'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 67,5 bn | 65,6 bn | 64,0 bn | 60,2 bn | 54,9 bn | 55,3 bn | 52,3 bn | 59,7 bn | 54,9 bn | 57,4 bn | 54,8 bn | 53,5 bn |
| EPS | 2,38 | — | 1,88 | — | — | — | 1,70 | — | 1,07 | 1,50 | 0,02 | — |
| Margin | 0,8% | 0,7% | 0,7% | 0,4% | 0,9% | 0,7% | 0,8% | 0,4% | 0,5% | 0,6% | 0,0% | −0,1% |
| FCF | 1,24 bn | 555 m | 865 m | 1,30 bn | 2,79 bn | −499 m | −1,74 bn | 1,88 bn | −161 m | 1,08 bn | 453 m | 641 m |
From SEC reports. TTM is the sum of 4 quarters; a year is TTM at the end of the calendar year. Forecast bars are in the paid data plan.
Owners
Ownership structure and major holders (13F filings) are in the paid data plan. They are not part of the score or the traffic light.
Insider trades over 12 months
Over 12 months: no purchases, sales $61,6 m.
| Name | Amount | Shares | Price |
|---|---|---|---|
| scherer mary c.19 Aug 2026 · sale | $522 733 | 2 202 | $237,39 |
| scherer mary c.19 Aug 2026 · sale | $23 740 | 100 | $237,40 |
| hollar jason m.19 Aug 2026 · sale | $1,49 m | 6 244 | $237,88 |
| hollar jason m.19 Aug 2026 · sale | $3,84 m | 16 187 | $237,23 |
| hollar jason m.19 Aug 2026 · sale | $1,59 m | 6 731 | $236,46 |
| hollar jason m.19 Aug 2026 · sale | $1,34 m | 5 704 | $235,34 |
| hollar jason m.19 Aug 2026 · sale | $809 941 | 3 457 | $234,29 |
| hollar jason m.19 Aug 2026 · sale | $1,45 m | 6 206 | $233,22 |
| greene michelle d.18 Aug 2026 · sale | $162 754 | 686 | $237,25 |
| greene michelle d.18 Aug 2026 · sale | $829 921 | 3 512 | $236,31 |
| greene michelle d.18 Aug 2026 · sale | $1,17 m | 4 952 | $235,68 |
| greene michelle d.18 Aug 2026 · sale | $586 425 | 2 500 | $234,57 |
| weitzman deborah18 Aug 2026 · sale | $66 721 | 281 | $237,44 |
| weitzman deborah18 Aug 2026 · sale | $96 529 | 408 | $236,59 |
| weitzman deborah18 Aug 2026 · sale | $1,57 m | 6 665 | $235,30 |
SEC Form 4. Titles and trading plans are not in the data. They are not part of the score or the traffic light.
About the company
- Industry
- Health Care
- Exchange
- NYSE
- Country
- US
- IPO date
- 4 Aug 1983
- Website
- www.cardinalhealth.com
Company description, revenue by segment and region, and the CEO will come later.
Earnings
- Next report
- date not announced
An AI summary of the earnings call will come later.
Peers
| Company | Price | ||||
|---|---|---|---|---|---|
BSXBoston Scientific | $43,69 | 83★★★★★★★★★would consider | 18,4 | +8,9% | 16,6% |
CORCencora | $356,94 | 83★★★★★★★★★would consider | 19,7 | +5,1% | 0,8% |
EWEdwards Lifesciences | $107,11 | 56★★★★★★★★would watch | 60,3 | +13,4% | 15,2% |
BDXBecton Dickinson | $216,47 | 38★★★★★★★would not consider | 51,8 | −2,6% | 4,5% |
IDXXIdexx Laboratories | $700,65 | 83★★★★★★★★★would consider | 47,2 | +11,9% | 25,4% |
Ratio — a score by our methodology, not an investment recommendation.




